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Angiogenesis’ Overall Effect on Health and
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The University of Louisville, Louisville, KY, USA
ABSTRACT
Angiogenesis is the process of forming new blood vessel and capillaries from pre-existing vessels. Angiogensis is the
foundation of reproduction and growth and as well as, responsible for healing of wounds and tissue repair.
Angiogenesis is a multistep process that involves the induction of angiogenesis by VEGF, destabilization of
extracellular matrix membranes, sprouting of vessels, migration of cells, and maturation. However angiogenesis is
also the root of cancer and age related dieseases such as muscular degeneration and several other major cardiovascular
diseases. There is evidence of various angiogenesis inhibiting therapies that are effective as a treatment method by
interfering with the development and growth of blood vessels and tumors. This article focuses on the the mechanism
of angiogenesis and how inhibiting angiogenesis is a crucial step in combatting cancer and disease. The article
discusses the potential of treatment therapies such monoclonal antibodies and consumption of foods that exhibit antiangiogenic properties such as fruits, vegetables, and berries.

INTRODUCTION
What is the leading cause of death in the U.S.? In 2019,
the leading cause of death was due to heart disease and
following behind is cancer according to the National Vital
Statistics System, Mortality, which remained the same in
2018. To understand the emergence of cancers and
diseases, the role of angiogenesis in disease and cancers
must be understood.
Angiogenesis is the process of forming new blood vessel
and capillaries from pre-existing vessels. Cell growth is
regulated by normal cell division, checkpoints and cell
signaling. Angiogenesis brings in oxygen and nutrients to
the body’s tissues allowing for the repair and healing of
developing or injured tissues. In pathologies, specifically
cancer, chemical signals and regulations are ignored by
the cells, and they continue to divide and become
cancerous. In abnormal angiogenesis, the blood vessel is
formed by angiogenic stimulators released to the
surrounding cells of a tumor mass that encourages the
growth of new blood vessels. In turn, angiogenesis
supplies the growth and metastasis of cancer cells
supplying the area with nutrients and creating a perfect
tumor microenvironment with angiogenic activators that
are manipulated to create more blood vessels. In
conclusion, angiogenesis plays both a crucial role in
health and disease. However, currently knowledge on the
effects of angiogenesis and angiogenic therapies are
limited and aren’t widely used. In this paper I review the
importance of relevant studies that explore a potentially
exciting treatment using anti angiogenic therapies for
disease and cancer treatment. This article will be an

overview of the promising anti-angiogenic therapies as
well as the methods and results of studies previously done
using angiogenesis inhibitors in various diseases such as
lung cancer and cardiovascular diseases. Without a doubt
regulating angiogenesis will benefit the advancement of
treatment in the field of medicine.

ANGIOGENESIS
The matrix is a dynamic structure undergoing consistent
deposition, degradation and modifications of its
components [1]. There are two types of known
angiogenesis, sprouting and the intussusceptive splitting
of preexisting blood vessels; both of which are triggered
by hypoxic tissues and are not very well understood [2].
Sprouting angiogenesis is the formation of new vessels
from existing blood vessels characterized by the sprouting
of endothelial cells triggered by VEGFs [2]. Without the
vascular network, the spread of cancer tissue would not
proliferate but be hindered in growth due to the lack of
angiogenesis [3].
The process of sprouting angiogenesis starts by the
activation of endothelial cells through growth factor
molecules or VEGF. VEGF are released by nearby
hypoxic tumor tissues and will later play an important
factor in sprouting angiogenesis, as they are sufficient in
triggering angiogenesis [4]. Endothelial cells are found in
the inner blood vessels lined by a single cell layer that
contains VEGF receptors. The expressions of these
specific receptors are bound by VEGF ligands on the
blood vessels of endothelial cells triggering a signaling
cascade and activates angiogenesis [5]. The binding of
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VEGF to VEGFR releases proteases, which encourages
the loosening of nearby blood vessel cells. Proteases,
specifically matrix metalloproteinases (MMPs) have the
ability to target many proteins, their targets include
growth factors-binding proteins, cell surface receptors,
cell-cell, cell adhesion molecules [6]. MMPs are the key
participant in tip cell functioning and breaking down the
basement and extracellular matrix (ECM) [7]. The ECM
is present in all cells and consists of various components
of different signaling molecules that are secreted from
mesenchymal cells that are important for development.
The loosening of the vessel cell allows for the sprouting
mechanism that forms an extension of endothelial cells as
a new vessel grow towards an angiogenic stimulus
VEGF-A [2]. As the capillary sprout emerges from
endothelial cells that will elongate, it extends the
filopodia and explores the microenvironment becoming
tip and stalk cells.
The mechanisms of notch signaling pathways and VEGFs
enforce a cascade that continuously re-evaluates with the
aid of many other signaling pathways that participate in
the regulation of specializing into tip cells [8].
Morphically, the tip cells will soon be joined cell to cell
by the merging of the vacuoles, which creates a uniform
lumen shared by many cells but a separated cytoplasm.
Tip cells contain receptors and exhibit migratory behavior
in endothelial cells during sprouting angiogenesis and
they sense the environment for guidance cues. The tip cell
expresses Netrin receptor uncoordinated-5B (UNC5B)
and Neuropilin (NRP), which will help detect attractive
signals from the tissue microenvironment and then follow
into a multistep processes of adhesion and detachment,
and leading to directed migration [7].
The tip cells form filopodia and lamellipodia which are
involved in cell migration. Filopodia are plasma
membranes that contain bundles of actin filament that aids
in the tip cells to probing their environment [7].
Lamellipodia are thin fan-like projections that are found
in the leading edge of many moving cells, such as
endothelial tip cells [9]. Lamellipodia are regarded as the
major driving force of mesenchymal cell migration in
both normal and disease-causing environments [10]. The
movements of cell migration are in the protrusion of the
leading edge, adhesion of the leading edge, de-adhesion
of the trailing edge, and then movement of the cell body
[11]. The mechanism starts with determining the direction
of the cell body, and then the cell extends a protrusion in
the direction of the movement via actin polymerization in
the leading edge. The cell then adheres the leading end to
the surface in the direction in which it is moving then deadheres the cell body from the rear [11]. On the contrary,
stalk cells are endothelial and proliferative but do not
form filopodia and follow behind tip cells [8]. Stalk cells
form the body and elongate as the sprouting occurs [12].
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However, it has been found that previously inhibited stalk
cells can be relieved from their inhibition and then
become tip cells [8]. In other words, tip-stalks do not
exhibit a fixed cell fate but instead, a dynamically
exchangeable phenotype specification fluctuation [8].
The uniform lumen will provide direct supply of oxygen
and glucose to the hypoxic tissue, providing a perfect
microenvironment. When the tissue flourishes because of
the oxygen it will increase in size, further develop, and
possibly exhibit more harm by metastasis. If the tumor
metastasis occurs, the tumor will travel to new places in
the body through blood vessels and capillaries in search
for a new environment to grow. In essence, the blood
vessels provide a route by which tumor cells exit the
tumor site and enter circulation [13]. Overall, tip cells and
stalk cells work together to form a vascular sprout that
grows towards the VEGR in response to the chemical,
mechanical factors, and some degree of random motility
[14].
Intussusceptive Angiogenesis is the lesser understood
angiogenesis method discovered after sprouting
angiogenesis, yet it is faster and lacks dependence on
endothelial cell proliferation for growth. The major
difference between this two angiogenesis’ is the presence
of pillars in the intussusceptive method, which are made
of connective tissue called tissue pillars, and inserted into
the lumen resulting in division of the lumen and an
increase in the density of the capillary network [15].
Sprouting and intussusceptive angiogenesis are both
critical to processes involving wound healing and
embryonic development. However over 70 diseases, such
as cancer and occlusive vascular disease relay on
angiogenesis for development and proliferation [16].
Angiogenesis plays such a huge role in disease and
illness, theocratically inhibiting angiogenesis could
prevent a lot of diseases and illnesses, since without these
factors (oxygen and nutrients) they wouldn’t adequately
meet the requirements to promote angiogenesis. Tumors
that grow bigger than a few millimeters will need oxygen
and nutrients in order to enlarge. Similarly, diseases like
cancer will need oxygen and nutrients in order to invade
nearby tissues and metastases, without it the cancer will
remain in a dormant state. In another relevant study done,
a region that lacked blood circulation the tumors grew to
a size of approximately 1-2mm3 before they halted.
Unfortunately, it was found that these tumors grew
beyond 2mm3 when placed in an area with angiogenic
support [17]. Therefore, if oxygen and nutrients are
inhibited from nourishing pathological tissues including
hypoxia, and the biochemical and physiologic pathways
that facilitate development of these tissues are altered and
intercepted in some way, then some diseases and illnesses
will not be successful in the development malignancy.
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Angiogenesis inhibitors express anti-angiogenesis
activity, while the tumor angiogenic switch seems to be
activated when the balance shifts from angiogenic
inhibitors to angiogenic stimulators [18]. Angiogenesis
inhibitors work by blocking the growth of the blood
vessels that support the tumor development rather than
inhibiting the growth of the tumor tissues.

MOLECULAR MEDIATORS IN ANGIOGENESIS
There are many molecular mediators that play a part in
angiogenesis. The vascular endothelial growth factor
(VEGF) is one of the most crucial molecular mediators in
the development of new blood vessels from existing blood
vessels. These molecular mediators that aid angiogenesis
keep the body healthy. Other growth factors that are a part
of the formation of new blood vessels like VEGF include
fibroblasts growth factor (FGF), tumor necrosis factoralpha (TNF- α), transforming growth factor (TGF-β), and
the angiopoietins (Ang) [19]. Expression of VEGF is
fundamental as it has an extensive range of functions and
acts jointly on many varieties of cell types, in essence
allowing for homeostasis in the human body. The ligands
of the VEGF family include VEGF-A, VEGF-B, VEGFC and VEGF-D and bind to VEGF receptors such as
VEGFR1, VEGFR2 and VEGFR3. VEGF plays a role in
the physiological processes of development that supply
blood and oxygen to cells through a series of vessels,
which allows for wound healing and increasing blood
flow to an area [20]. The ligand VEGF-A/receptor
VEGFR-2 signaling appears to be more frequent and
distinguished as the predominant mediator involved in the
angiogenesis pathway [14]. Increasing blood flow and
angiogenesis can benefit certain health related problems
like heart disease, arterial disease, and promote wound
healing. Other physiological processes that are associated
with upregulation of VEGF/VEGFR- system include
VEGF being widely expressed during the female
reproductive cycle, reproductive cycle, as well as bone
repair [21].
On the other hand, increased angiogenesis is nontherapeutic and harmful in the case of tumor development
and growth, sepsis, arthritis and other diseases. Tumor
angiogenesis is stimulated by VEGF through several
mechanisms, including enhancing endothelial cell
proliferation and survival; increased migration through
the formation of lattice network and invasion of
endothelial cells; and enhancing chemotaxis [22].
Therefore, it has been concluded that inhibiting VEGF
would interrupt the growth of tumors as it plays such a
vital role in the formation of blood vessels. Inhibition of
VEGF signaling with anti-VEGF strategies were designed
to target abnormal angiogenic production and used in
anticancer therapy. Many molecules and proteins such as
small molecules (kinase inhibitors), peptides, antibodies
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and aptamers play a critical role in the body in the
formation
of
complex
macromolecules
and
immunological protection from intrinsic and extrinsic
factors. These important agents create essential building
blocks that allow for the healthy functioning of the body.
Interestingly enough, it has been confirmed that using
these agents and combination of other treatments, have
the potential to work against and block VEGF and be used
as a treatment in cancer patients. Cancers lacking
angiogenesis will remain latent and tumors do not grow if
blood isn't supplied which is why angiogenesis is an
important topic in medicine. In clinical trial patients with
lower levels of VEGF expression, survival was
significantly greater than patients with higher levels of
VEGF expression found in the body. The first FDA
inhibiting angiogenesis target therapy drug, bevacizumab
was officially approved in patients with metastatic
colorectal cancer, metastatic breast cancer, lung cancer,
renal cell carcinomas and glioblastoma multiforme [23].

ANGIOGENESIS INHIBITORS
There are various therapies including angiogenesis
inhibitors being used as a treatment method by interfering
with development and growth. Monoclonal antibodies are
laboratory made molecules that act as a human antibody
protecting our immune system by mimicking natural
immune system functions. Monoclonal antibodies are one
of the most significant strategies for treatment of cancer
and other diseases. Examples of some monoclonal
antibodies that act as angiogenesis inhibitors are
Bevacizumab (Avastin), Aflibercept (Zaltrap) and
Ramucirumab (Cryramza) [24]. These monoclonal
antibodies work by targeting VEGF and VEGFR in the
body.
Bevacizumab (Avastin) is a recombinant humanized
immunoglobulin G (IgG) monoclonal antibody that
targets VEGF-A and inhibits formation of the VEGF-A
and VEGFR-2 complex [24, 25]. In 2004, US FDA
approved Bevacizumab for treatment of metastatic
colorectal cancer with a combination of chemotherapy
[26]. Currently Bevacizumab is used on patients with
various cancers, metastatic renal cell carcinoma, breast
cancer, epithelial ovarian cancer, glioblastoma [24, 2731]. As a result of successful clinical validation in patients
who had taken bevacizumab to as act the specific inhibitor
of VEGF-A/VEGFR2 interactions, there has been an
increase of monoclonal antibody development to target
VEGFR2 since it showed promising results for antiangiogenesis [24].
Aflibercept (Zaltrap) is another monoclonal antibody that
suppresses tumor angiogenesis by tricking VEGF-A,
VEGF-B and PIGF [24]. In 2012, the FDA approved
aflibercept to be used as a treatment on patients with
resistant and progressive metastatic colorectal cancer
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[32]. The FDA also approved aflibercept (Eylea) to be
used as treatment on patients with wet age-related
muscular degeneration, which is responsible for one most
common cause of blindness in the elderly [32, 33].
Ramucirumab (Cyramza) is a monoclonal antibody that
targets VEGFR-2 and is used in combination with
paclitaxel
to
treat
patients
with
advanced
gastroesophageal cancer and have progressed after initial
treatment [34]. It was approved by the FDA for non-small
cell lung cancer patients, results from phase 3 of clinical
trial showed promising results and even greater benefit for
patients with aggressive tumor behavior of this antibody,
however it has been found that Ramucirumab can cause
severe toxicity in patients [35]. Other treatment therapies
include consumption of foods that exhibit antiangiogenesis properties. For example, these include
fruits, vegetables, berries, parsley, and green tea.

GREEN TEA ANTI-INFLAMMATORY AND ANTICANCER PROPERTIES
The consumption of tea, specifically green tea, has been
shown to inhibit the growth of angiogenesis. Green tea
comes from dried tea plants of the Camellia sinensis
family. Green tea has many benefits for the body, besides
being rich in antioxidants research has found that drinking
green tea may promote the prevention of disease.
Polyphenols are the chemicals found in green tea that
have antioxidant potential and are classified as catechins.
Researchers have found that the extract of green tea
contains high amount catechins that reveal antitumorigenic activity and anti-inflammatory capabilities
[36]. Recent scientific research suggests that catechins
exhibits efficient prevention of lung cancer, liver cancer,
esophageal cancer, and prostate cancer [37]. Another
research suggests that green tea consumption improves
circulation and promotes vessel dilation which can be a
preventive measure in chronic smokers from
cardiovascular related diseases [38]. Overall catechins
found in green tea have exhibited anti-carcinogenic,
antimutagenic, anti-inflammatory mechanisms [39]. This
is the reason why green tea has been heavily focused on
as an anti-cancer and anti-inflammatory preventative.

GREEN TEA AND NSAIDS COMBINATION
SYNERGISTIC ANTI-CANCER EFFECTS
In a study done in Japan in 1983, at the National Cancer
Center Research Institute in Tokyo and Saitama Cancer
Center Research Institute they have found that the main
catechins found in green tea includes 10-15% of
epigallocatechin gallate (EGCG), 6% to 10%
epigallocatechin (EGC), 2% to 3% epicatechin gallate
(ECG), and 2% epicatechin (EC) [40]. Out of the main
catechins found, EGCG is the most abundant and active
catechin found in green tea followed by EGC and ECG, it
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has been found that all of the catechin exhibit cancer
preventive activity besides EC. It appears to be an inactive
tea catechin and does not reveal effective anticancer
activity, however when EC is combined with EGCG as a
treatment it showed synergistic effects on apoptosis
performance [41]. Many studies have been done on
rodents targeting many organs with EGCG, the results
reported that EGCG and green tea catechins can have
systemic effects on cells towards anticariogenic activity
[42]. Consuming a certain amount of green tea per day has
seen a potentially preventative effect on lung , colorectal,
liver and stomach [43, 44] and breast cancer [45]. In
patients with breast cancer, it has shown that EGCG
interfered with the function of estrogen receptors,
inhibited cell proliferation of estrogen-induced breast
cancer and increased the sensitivity of the tumor to drugs
that target steroid receptors [46-48].
The outcome and success level of using EGCG as an antimalignant and repressor of cancer differs in different
types of cancer and per individual. It has been found that
a combination of EGCG and nonsteroidal antiinflammatory drugs (NSAIDs), like sulindac, acting
synergistically for enhanced anticancer activity while
treatment with either EGCG or sulindac alone have only
a minor effect on promoting anticancer activity [49]. In
conclusion when EGCG and green tea catechins are used
in combination with other anticancer compounds,
repression of tumor growth and anticancer effects
increased in various human cancer cells [40].

SUBJECT AND METHODS
Angiogenesis inhibition in cancer prevention as a result
of drinking green tea is significant because it’s
inexpensive, easily accessible, and not very time
consuming. Drinking green tea daily can lower your risk
of contracting cancer and improve your overall health.
The antioxidants in green tea such as catechins inhibit
angiogenesis naturally without the aid of medication. This
is extremely relevant in today’s society as many people
are heavily reliant on medication and never have enough
free time to worry about their personal health. This study
focused on the preventative effects of the consumption of
green tea and the significance of green tea in the
prevention of and to decrease the risk of cancer and
disease, like cardiovascular diseases, which are often
observed in patients with lung cancer [44]. The study was
done in 1986 in Saitama, Japan in residents over the age
of 40 of 8,552 individuals. They first initiated this study
by conducting a questionnaire covering 90 lifestyle
factors, and then organized the results. From 1986 to
1997, a timespan of 11 years, there were a total of 488
cancer cases. They organized the results on green tea
consumption in these categories, below 3,4-9 and over 10
cups a day on these cancer patients. They had found the
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most common cancer in both sexes, in order, were cancers
of the stomach, lung, colon, rectum and liver [44].

RESULTS
It was concluded among women who had high
consumption of green tea, consuming over 10 cups a day
had the most significant decrease in cancer by as much as
40%. Although, all categories of women who drank below
3 or 4-9 cups a day all show decreased signs of cancer
[44]. Interesting enough, the results between women and
men were opposite for those consuming over 10 cups a
day. Among men who had high consumption of green tea,
consuming over 10 cups a day suggested an increased rate
of cancer incidence [44]. The reasoning for the increased
cancer incidence in men when consuming over 10 cups of
tea a day, was that those who were consuming the greatest
amount of tea also had increased cigarette consumption.
This was deemed true, as the results revealed that among
men who never smoke and those who quit smoking both
showed a decrease in cancer incidence with a higher
amount of green tea consumption daily [44]. In both male
and female, it showed a correlation and association of
decrease in cancer incidence in those who were
nonsmokers and those who quit smoking with
consumption of over 10 cups of tea daily. Those
consuming below 3, 4-9 and over 10 cups a day showed
an exponential decrease in cancer incidences [44].
Proceeding, the team studied the effect of green tea based
on the type of cancer. For example, consumption of a high
amount of green tea daily had the greatest impact for
individuals who had lung cancer in both males and
females [29]. In conclusion the study showed that green
tea exhibits some preventative effects of cancer,
specifically lung cancer and decreased incidences of
cancer for those consuming over 10 cups a day without
tobacco use.

CONCLUSION
Cancer and disease are the leading causes of death in the
United States every year. Angiogenesis has shown to
exhibit a role in disease and health as it is the main
mediator in healing as well as the proliferation of tumors
and malignant diseases. While angiogenesis is a natural
process that takes place in the course of life development,
it ultimately exacerbates tumor growth in cancer patients.
VEGF and VEGFR signal angiogenesis and play a crucial
role in healing and the development of diseases; it is
advantageous in cases with heart disease and arterial
disease, but disadvantageous to individuals with lung and
breast cancer. Treatment therapies targeting VEGF and
VEGFR in the body include the consumption of foods that
exhibit anti-angiogenic properties. For example,
vegetables, berries, parsley and specifically green tea.
Monoclonal antibodies have been developed targeting
VEGF and VEGFR, these antibodies include
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Bevacizumab (Avastin), Aflibercept (Zaltrap) and
Ramucirumab (Cryramza). Green tea contains a high
content of EGCG, which has been found to inhibit
angiogenesis through cell proliferation, apoptosis, and
inhibition of angiogenesis expression. Particularly, this
paper discussed the cohort study on the effect of green tea
on disease prevention and the correlation of the decrease
in cancer incidences in individuals who consumed a high
amount of green tea daily. Green tea exhibits a
preventative effect in cancer, specifically lung cancer and
decreases the incidences of cancer for those consuming
over 10 cups a day.
To conclude, angiogenesis has a major role in both
healing and the development of diseases, many
monoclonal antibodies have been developed to inhibit
angiogenesis and the efficacy varies depending on the
type of cancer. For a natural route, foods that contain
EGCG, for example in fruits, vegetables, berries, parsley,
and specifically green tea have shown a preventative
effect on cancer.
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